Published in final edited form as:

Neuroscience. 2012 June 1; 211: 2–12. doi:10.1016/j.neuroscience.2012.03.024.

Animal models of eating disorders

Sangwon F. Kim

Department of Psychiatry and Pharmacology, Center for Neurobiology and Behavior, The Perelman School of Medicine University of Pennsylvania, 125 S 31st St. TRL Rm 2207, Philadelphia, PA 19104

Abstract

Feeding is a fundamental process for basic survival, and is influenced by genetics and environmental stressors. Recent advances in our understanding of behavioral genetics have provided a profound insight on several components regulating eating patterns. However, our understanding of eating disorders such as anorexia nervosa, bulimia nervosa, and binge eating is still poor. The animal model is an essential tool in the investigation of eating behaviors and their pathological forms, yet development of an appropriate animal model for eating disorders still remains challenging due to our limited knowledge and some of the more ambiguous clinical diagnostic measures. Therefore, this review will serve to focus on the basic clinical features of eating disorders and the current advances in animal models of eating disorders.

Keywords

Animal models; Eating disorders; Anorexia; bulimia; Binge eating; obesity

Introduction

Energy homeostasis is essentially a balancing act between food intake and energy expenditure via basic metabolism or physical activities (Feige and Auwerx, 2007; Gao and Horvath, 2007). Eating disorders such as anorexia nervosa, bulimia nervosa, and binge eating are described as disturbances in eating habits usually involving insufficient or excessive food intake. These abnormal eating patterns cause energy imbalance resulting in the detriments to the individual's wellbeing (Sodersten et al., 2006; Thornton et al., 2011; Weiselberg et al., 2011). These disturbances are not limited to alteration of diet choices but also include abnormal psychological perceptions towards food, eating, body weight and self-image. The etiology of eating disorders has yet to be characterized, but it is evident that the cause is multifactorial. The current identified causes of eating disorders are cultural pressures, biology, environment and genetic predisposition. (Sodersten et al., 2006; Weiselberg et al., 2011).

Animal models have been a powerful tool in researching neuropsychiatric conditions (Fernando and Robbins, 2011; Samyai et al., 2011). A well characterized etiology is always

© 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

To whom correspondence should be addressed: Sangwon F. Kim, Tel: 215-746-3657, Fax: 215-573-2041, sangwonk@mail.med.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

a good basis for developing appropriate animal models for any disease state. For example, if genome wide association studies have provided a potential risk gene for a disease in humans, the homologous genes can usually be easily mutated or deleted in animal models (Fernando and Robbins, 2011). While the causes of some diseases may not always be characterized, the understanding of disease progression and treatment may be useful in developing an effective animal model. Unfortunately, the lack of such information has hampered the efficient utilization of animal models to investigate eating disorders (Casper et al., 2008; Smith, 1989). Moreover, due to the complex nature of eating disorders, current animal models can only provide a few characteristic traits of the human psychiatric disease. Despite this setback, many scientists in the field are able to develop powerful paradigms to study specific aspects of eating disorders.

In this review the clinical, behavioral, and physiological features of anorexia nervosa, bulimia nervosa, binge eating disorder as well as obesity, although not specifically characterized as an eating disorder, will be discussed, followed by the understanding of how scientists can recapitulate these conditions in animal models. This will be followed by an overview of utility and limitations of the different available animal models for eating disorders and obesity relevant to the human condition.

One of the major hurdles animal models face is that they cannot show multiple traits of human psychiatric diseases. As an alternative approach, non-human primate models have been utilized to investigate the complex behavioral, social, and genetic interactions (Nelson and Winslow, 2009). However, these non-human primate models have their own disadvantages; 1) non-human primates are much more expensive to maintain than non-primates, 2) it is extremely time-consuming to develop their model systems 3) Behavior testing in primates is not standardized. Even with these limitations, non-human primate models have contributed greatly to certain experimental questions addressing social and complex cognitive interactions. Because of these drawbacks to the usage of non-human primates as models of eating disorders it is necessary to develop other, more practical vertebrate animal models.

Anorexia Nervosa

Anorexia nervosa (AN) is the most common eating disorder which primarily affects teenage girls at puberty. It is characterized by chronic food refusal, excessive weight loss, an intense fear of weight gain and a distorted self-image including body shape and weight (American Psychiatric Association, 2000; Attia, 2010; Weiselberg et al., 2011). It usually manifests with an innocent effort to reduce caloric intake which gets out of control. Individuals with AN continue to feel hunger, yet deny themselves by restricting food intake (Attia, 2010; Garfinkel, 1974). The first major clinical symptoms are derived from psychological changes which can be characterized as motivated refusal to eat and maintain a body weight above 85% of the standards, intense fear to gain weight. These symptoms can be exacerbated by physiological and endocrine changes caused by the shortage of food or energy intake. A significant weight loss below 85% of normal weight for age and height or a body mass index below 18 is generally the first noticeable signs of AN (American Psychiatric Association, 2000; Hebebrand et al., 2004). Obviously, the extreme weight loss associated with AN can lead to endocrine disturbances such as amenorrhea, the absence of menstrual periods for post-pubertal females. Also, plasma leptin levels, which normally is secreted from adipose tissue after feeding is reduced in AN patients (Hebebrand et al., 2003; van Elburg et al., 2007). Most of the endocrine changes that influence the regulatory system in AN are a reflection of the body's adaptation to an extended exposure to malnutrition (Casper and Davis, 1977). Many people going through prolonged starvation due to either religious or clinical reasons experience fatigue and slowed activity levels (Casper, 1998). However,

individuals with AN tend to exhibit high activity levels as well as mental alertness during their weight loss from food restriction. This in turn drives them to engage in excessive exercise creating a detrimental positive feedback/reward cycle (Casper, 1998; Casper et al., 1991; Klein et al., 2007; Pirke et al., 1991).

AN patients commonly display comorbid psychiatric symptoms such as anxiety, obsessive-compulsive disorders, and depressive disorders (Attia, 2010; Casper and Davis, 1977; Casper et al., 1979; Mattar et al., 2011; Ploog and Pirke, 1987). Malnutrition is thought to augment these symptoms because the disturbance of neurotransmitter levels is restored after nutritional restoration. One of the classical studies by Keys et al also showed that these psychiatric symptoms can be derived from malnutrition (Keys et al., 1950). In this study, healthy male volunteers were subjected to a semi-starvation condition for three months. The group found not only the typical physiological changes due to malnutrition, but also psychiatric symptoms such as depression, obsessive-compulsive like, and psychosis-like behaviors, which are very common among patients with eating disorders (Keys et al., 1950). Since the publication of this study, it has been debated whether psychiatric symptoms observed in patients with AN, or any eating disorder, are the cause or consequence of malnutrition.

Recent studies have illustrated that most people with AN (or other eating disorders) show childhood anxiety and perfectionism, or obsessive-compulsive, personality patterns prior to the onset of an eating disorder (Lilenfeld et al., 2006). These studies suggest that patients displaying these symptoms may be susceptible to developing eating disorders later in life. Malnutrition appears to enhance these pre-morbid behavioral traits, rather than causing them. Moreover, studies have also shown that some traits such as perfectionism, negative emotionality, harm avoidance (a multifaceted temperament trait that contains elements of anxiety, inhibition, and inflexibility) still persist long after a recovery from AN (Deep et al., 1995).

Patients with AN have significantly reduced CSF serotonin (5-HT) metabolites compared to control subjects (Kaye et al., 2005; Stanley et al., 1985). More recent imaging studies showed that 5-HT_{1A} is increased while 5-HT_{2A} is not elevated in both ill and recovered AN patient brains (Audenaert et al., 2003; Bailer et al., 2007; Galusca et al., 2008). These changes in receptor expression may be a compensatory mechanism to respond to a decrease in 5-HT levels. An increase in food intake, in particular carbohydrate intake, enhances extracellular 5-HT levels. This change may potentiate the effect of 5-HT_{1A}, which is positively associated with harm avoidance in patients suffering from AN. Therefore, it is possible to speculate that malnutrition in AN patients have reduced 5-HT levels and consequently, decreased dysphoric mood. Despite numerous studies supporting the involvement of 5-HT AN, serotonin reuptake inhibitors (SSRIs) showed very limited success in reducing moods or other core psychiatric symptoms in AN patients (Attia and Schroeder, 2005). Nevertheless, it is tempting to speculate that imbalances between 5-HT_{1A} and 5-HT_{2A} contributes at least in part, to such traits of AN, but further studies are needed to make this conclusion.

People with AN engage in exercise compulsively, and this trait also tends to remain after recovery (Klump et al., 2004; Shroff et al., 2006). The dopamine (DA) pathway plays a critical role in compulsive and addictive behavior. Recently, it has been shown that DA metabolites in ill and recovered AN individuals are reduced in CSF (Kaye et al., 1999). Also, PET studies show that those who recovered from AN had increased D₂/D₃ receptor in ventral striatum, an area which responds to reward-stimuli (Frank et al., 2005). In particular, DA in ventral striatum plays a role in motivational aspects to stimuli (Montague et al., 2004; Schultz, 2004). Alteration of DA system in this area may explain the difficulty of

motivating AN patients for treatment. While typical and atypical antipsychotic drugs target the DA system, previous studies examining the effect of typical antipsychotic drugs whose target is limited to DA system did not show any significant changes in food intake (Lambert and Porter, 1992). However, atypical antipsychotic drugs, (AAPDs) would be exciting drugs to examine for this disorder and deserve further studies. AAPDs interact not only with DA but also 5-HT (Miyamoto et al., 2005). One of the side effects of AAPDs is weight gain (Ananth et al., 2004; Newcomer, 2005; Teff and Kim, 2011), which would be a welcomed effect for patients with AN. Current studies show that olanzapine treatment induces a decrease in anxiety and depression in AN patients (Bissada et al., 2008), but a larger scale study is required to determine whether this type of AAPD has any effect on improving food consumption in AN patients.

Animal models

Self-starvation/Activity based anorexia(ABA)

Self-motivated caloric restriction is characteristic of eating disorders, especially in AN. Many animal models fail in this aspect because food intake is controlled by experimenters. However, in a self-starvation model, an environment is created such that animals must “choose” between food intake or another rewarding condition such as brain stimulation or exercise.

ABA is an animal model, which recapitulates a subset of key characteristics of AN, especially hyperactivity and reduced food intake. Considering main physiologic characteristics, reduced body weight in AN, it is not surprising to see a significant reduction in leptin levels, as leptin is an adipose-derived hormone (Leibowitz and Wortley, 2004; Wynne et al., 2005). AN patients also exhibit reduced leptin levels in plasma and cerebrospinal fluid (CSF) (Exner et al., 2000; Holtkamp et al., 2006). Upon leptin administration to ABA rodents or AN patients, hyperactivity was suppressed (Hillebrand et al., 2005). The mechanism underlying hyperactivity in AN despite a negative energy balance is still unclear. ABA is also known as semi starvation-induced hyperactivity or activity anorexia. Activity-induced hypophagia was initially introduced in 1967 using running wheels (Routtenberg and Kuznesof, 1967). This model reproduces the main hyperactivity behaviors characteristic of AN: reduced food intake in the presence of hunger, weight loss, desire for activity along with physiological responses of malnutrition. Under a restricted food schedule, such as 60 min of feeding per day, ABA rodents still maintain normal bodyweight (Avraham et al., 2001a; Routtenberg and Kuznesof, 1967). However, once a running wheel is introduced at all times except for the time when they eat, their food intake gradually starts to decrease. Eventually, energy expenditure by wheel running exceeds caloric intake and they starve themselves to death. In contrast to ABA rodents, control ad libitum fed rats with continuous access to running wheels show stable levels of running wheel activity as well as an increase in food intake to compensate for increased energy expenditure (Kas et al., 2003). Moreover, control rats on restricted feeding schedule without running wheels exhibit an increased food consumption and marginal body weight loss compared to ABA rats (Kas et al., 2003). ABA rats are a very relevant model mimicking AN as these animals can overcome the basic homeostatic mechanism for survival under this model. Furthermore, female ABA rodents exercised more than male rats during the starvation-exercise model (Pirke et al., 1993). Under this activity model, decreased food intake is associated with the increased 5-HT levels in hypothalamus similar to stress models (Avraham et al., 2001a). This gender difference is also an area requiring further investigation, as it correlates with human distribution of AN among genders. Routtenberg et al showed that when ABA rats were given a choice between eating food and pressing a lever for positively reinforcing electrical stimulus in posterior hypothalamus, rats chose stimulation reward (Routtenberg and Kuznesof, 1967). This experiment strongly implicates

that patients with AN may have imbalances in the reward system influenced by distorted self-image or societal pressures and gain more pleasure from weight loss than maintaining a healthy life-style (Casper et al., 1979; Eckert et al., 1979; Ploog and Pirke, 1987).

Stress models

Stress-mediated changes in hypothalamus-pituitary adrenal axis (HPA) can affect food intake (Jahng, 2011; Lo et al., 2008). Indeed, it has been reported that hormonal imbalances in the HPA via a life stressor is frequently involved with some forms of eating disorders. The stress-mediated eating behavior is one of the most widely used models because it does not require the manipulation of food availability. There are many stress models which can induce weight loss in animals such as cold swimming, tail pinching, and direct brain stimulation (Shimizu et al., 1989; Wilson and Cantor, 1986). It is well known that stress can lead to weight loss and contribute to a loss of appetite but caution must be taken into consideration when utilizing such models to study AN, as excessive manipulation such as electrical stimulation of the brain can physically harm the animals. In recent years, chronic and mild forms of stressors have been introduced to induce weight loss. One example is the novelty environment, wherein mice are introduced to surroundings to which they have not been previously exposed. Utilizing this model, Asaka's group showed that corticotropin-releasing factor is activated and subsequently, peripheral levels of ghrelin, orexigenic peptides are reduced (Saegusa et al., 2011).

Physical isolation can induce a depression-like condition with reduced food intake and cognitive function. Mice are housed in a cage with individual partitioning so that they can see and smell each other without physical contacts except at feeding time. This model overcomes some shortcomings of other stress models to induce weight loss, as it does not involve any physical harming of animals. Previous studies show that separation-mediated stress decreases dopamine and norepinephrine in the hippocampus. It appears that this stress-mediated loss of appetite is induced by increased serotonin (5-HT) levels in the hypothalamus as administration of 5-HT receptor antagonist prevents weight loss under these conditions. However, it is important to point out that it is unlikely that stress-mediated imbalance of 5-HT itself is a direct cause of AN even though it can trigger weight loss. In particular, individuals with AN appear to have reduced 5-HT levels.

Diet restriction

It has been shown that caloric restriction extends life-span in various laboratory animal species with improvement of many pathological genetic changes during ageing (Spindler, 2010). However, excessive food restriction of less than half of daily ad libitum intake can be used as AN model. A significant drawback to this model is that unlike individuals with AN, food restriction is not voluntary. Nevertheless, many of changes in the neuro/endocrine systems observed in AN can be mimicked by diet restriction alone in mice. Under the chronic food restriction model, rats exhibited reduced cognitive function (Campbell and Bedi, 1989; Idrobo et al., 1987; Yokogoshi and Nomura, 1991). Tyrosine supplementation in this model improved cognitive function without changing body weight (Avraham et al., 2001b). This may have important implications in treating patients with AN as many patients frequently do not respond well to psychological treatments during nutritional rehabilitation, which is typically accompanied by weight gain (Attia, 2010; Avraham et al., 2001b; Casper, 1998).

Genetic model

A remarkable flurry of genetic research pertaining to eating behaviors in the past decade has identified a large number of novel genes whose products are important players in regulating food intake and energy balance. Many animal models mutating these targets genes produce

an obesity phenotype, which will be briefly discussed later in this review although it is not considered an eating disorder. The Obesity gene functions are well characterized in animal models, yet very few anorexia or hypophagia genetic models are available. Moreover, there is no direct evidence to correlate genetic alternation to human AN. Nevertheless, this has clear advantages. In genetic model, specific genes which may lay on the potential pathways contributing to etiology of AN can be directly examined. Moreover, genetic modifications generate more stable and reproducible phenotypes.

The most commonly studied genetic model of AN is *anx/anx* mice. The autosomal recessive *anx* mutation in rodents is reported to have decreased food intake behaviors, so extreme it causes death within 20–30 days after birth (Johansen et al., 2003). Moreover, the mice are characterized by reduced body weight, body tremors, head weaving, hyperactivity and uncoordinated gait. These mice have reduced serum leptin levels and show abnormalities in the orexigenic (NPY and AgRP) and anorexigenic (POMC and CART) pathways (Broberger et al., 1999; Broberger et al., 1998a; Broberger et al., 1998b; Johansen et al., 2000). In particular, immunohistochemical analysis revealed that NPY and AgRP neuropeptides are accumulated in cell bodies rather than dendrites of affected animals. Considering that leptin, which is produced in adipose tissue and modulates these neuropeptides, is lacking in *anx/anx* rodents, it is not too surprising to observe deregulation of these neuropeptides (Zarate et al., 2004). A recent study revealed that *anx/anx* mice displayed hypothalamic degeneration accompanied by inflammatory responses (Nilsson et al., 2011; Saegusa et al., 2011) and they fail to regulate food intake.. This raises a slight concern about this model for AN, as individuals with AN typically feel hunger and yet refuse to consume food unlike the *anx/anx* mouse model.

Brain-derived neurotrophic factor (BDNF) plays various key roles helping to support the survival of existing neurons, and promote the growth and differentiation of new neurons and synapses (Nagahara and Tuszynski, 2011). Ribases et al explored a possibility of BDNF as a potential gene associated with AN after observing that BDNF knockout leads to an increased food intake, while intraventricular administration of BDNF results in reduced food intake and weight loss in rats (Ribases et al., 2003). They also reported a strong correlation between weight loss induced by restricting AN, and a point mutation in BDNF (Val66Met). However, recent studies failed to demonstrate the preferential transmission of the 66Met allele of BDNF in AN (Brandys et al., 2011; Dardennes et al., 2007).

Several neurotransmitters have been proposed to be perturbed in eating disorders but monoamine systems, in particular dopamine and serotonin pathways have been researched most extensively. Recent imaging studies with positron emission tomography showed altered serotonergic and dopaminergic neuronal pathway activities (Frank et al., 2005; Kaye et al., 1999). Dopamine deficient (DD) mice lacking the dopamine synthesizing enzyme, tyrosine hydroxylase, in dopaminergic neurons become hypophagic and hypoactive and die of starvation at 34 days (Szczypka et al., 2001). Their phenotypes can be reversed by daily administration of L-DOPA or by viral gene-delivery of tyrosine hydroxylase (Hnasko et al., 2006).

It is established that disturbances in opioid receptors are associated with feeding. Because of this association, it is likely to play a role in AN. Moreover recent genome wide association study further confirmed that delta opioid receptor (OPRD1) is a risk gene (Brown et al., 2007). Studies have shown that disturbances in ORD1 receptors can lead to an auto-addiction to fasting and exercise. Mouse models with ORD1 receptor genes knocked out can be a useful tool in analyzing this aspect of eating disorders (Rask-Andersen et al., 2010). When ligand for ORD1, orphanin FQ, is injected to rats, it induces hyperalgesia and

induces feeding in satiated animals. When an antagonist is introduced to this system, feeding is inhibited and returned back to normal (Pomonis et al., 1996).

Feeding behavior and satiation is also affected by serotonergic neurotransmission. 5HT stimulation, via agonist in mice, inhibits food intake, suggesting that 5-HT is associated with satiety (Mancilla-Diaz et al., 2005). In both animal models and humans, agonist stimulation decreases the rate and meal size. 5HT-1B seems to be responsible for amount of food intake while 2C controls rate of eating. However, drugs that induce 5-HT_{1A} increase food intake (Simansky, 1996). Because of this multifactorial response, animals with genetic deletion of different 5-HT receptors act as a good genetic model to study AN and BED.

Mice deficient of the M3 muscarinic receptor (M3R^{-/-}) show a decrease in food intake and subsequent reduced body weight, low levels of serum leptin and insulin, and a significant elevation in basal and total energy expenditure (Qu et al., 1996; Shimada et al., 1998). In these mice, AgRP levels are elevated while POMC is decreased. This appears to be a reflection of negative energy balance. Interestingly, hypothalamic melanin concentrating hormone (MCH), which promotes feeding, is significantly reduced in these mice. The combination of the reduced expression of MCH as well as a lack of AgRP activity plays major role on the hypophagic phenotype in these mice. Mice which lack MCH have a hypophagic phenotypes and an increased metabolic rate. These mice have normal levels of orexigenic peptides such as AgRP and NPY, but POMC is reduced even though leptin levels are decreased. M3R^{-/-} mice are more susceptible to weight loss after food deprivation compared to wild type mice and majority of MCH deleted mice die after 48 hours of starvation (Shimada et al., 1998).

Despite limited proof of a specific genetic component, evidence supports a strong genetic correlation in susceptibility to AN. A recent study by Wang et al identified common single-nucleotide polymorphisms (SNPs) within *OPRD1* (rs533123) that confer risk for AN, and obtained suggestive evidence that common SNPs near *HTR1D* (rs7532266) impart risk for restricting-type AN. These evidences suggest that both common SNPs and rare CNVs may pose a genetic risk for AN (Wang et al., 2011). Compared with other psychiatric disorders, AN is more likely to be associated with socio-cultural differences, which complicates traditional genetic studies, but identification of these susceptibility gene(s) by genome-wide association study will help researchers design appropriate animal models.

Bulimia nervosa/Binge Eating

Bulimia nervosa (BN) is described as recurrent episodes of binge eating at least twice weekly for 3 months with a sense of inability to control over eating also associated with repeated compensatory behaviors such as vomiting, and excessive exercise (American Psychiatric Association, 2000; Mathes et al., 2009). Unlike AN, which has long documented history, BN is a relatively new syndrome, first described in 1979 (Russell, 1979). In *Diagnostic and Statistical Manual for Mental disorders-V (DSM-V)*, the binge eating phase of BN is characterized by both of the following: first, an affected person will binge eat in a defined period of time, an amount of food that is much larger than most people would eat during a similar period of time and under similar circumstances. Secondly, the affected individual has one of five traits; 1) a lack of control over eating during the binge episode. 2) Recurrent inappropriate compensatory behavior in order to prevent weight gain, such as self-induced vomiting, fasting, excessive exercise or a misuse of laxatives, or other medications. 3) The binge eating and inappropriate compensatory behaviors both occur, on average, at least once a week for 3 months. 4) Self-evaluation is primarily influenced by body shape and weight. 5) The binge disturbance does not occur during episodes of anorexia nervosa (<http://www.dsm5.org/>). BN exhibit a high co-morbidity with affective disorders (Brewerton

et al., 1995); substance abuse is frequently associated with BN (Strober et al., 1999). Furthermore, it appears that patients with BN history are more sensitive to stress than those with AN, suggesting that stressful environment can easily trigger binge eating.

A similar eating disorder to BN is Binge Eating Disorder (BED), which has similar diagnostic criteria as BN; a large amount of consumption, or a loss of self-control. In addition, a definition of “binge” in either BED or BN also includes temporal dimension such as within 2 hour period for food consumption (Cooper and Fairburn, 2003; Latner and Clyne, 2008; Wolfe et al., 2009) once a week for 3 months. However, diagnosis of BED has to be associated with at least 3 following characteristics; 1) Eating much more rapidly than normal. 2). Eating until feeling uncomfortably full. 3). Eating large amounts of food when not feeling physically hungry. 4). Eating alone because being embarrassed of how much one is eating, and 5). Feeling disgusted with oneself, depressed, or very guilty after overeating (American Psychiatric Association, 2000). Moreover, binge eating in BED is not associated with the regular use of inappropriate compensatory behaviors (Cooper and Fairburn, 2003). Although BN and BED share many clinical symptoms, they have distinct diagnostic criteria which are the primary basis to develop separate animal models. Notably, traits that differentiate the two disorders such as binge eating for 6 months versus 3 months, or a lack of compensatory behavior in BED are impossible to recapitulate animal models, therefore, BED and BN appear to share the same animal models until other characteristics which can be manipulated in a laboratory setting such as different susceptible genes can be explored.

Food restriction

Food restriction or deprivation can induce increased food intake in animals. It has been shown that with as few as 2 hours of food restriction in rats, triggers an increase in food consumption (Cottone et al., 2008; Hagan et al., 2003). Increased food consumption is apparent within 2 hours of restriction, after reintroducing food, a “binge-like” food intake persists for at least 4 hours. Other studies have explored food restriction and refeeding paradigms by exposing animals to repeated fasting episodes to induce moderate weight loss, subsequently followed by periods of re-feeding for animals to regain their normal weight levels (Hagan and Moss, 1991; Specker et al., 1994). When animals lost 20–35% of their normal weight, the animals showed significant binge-like eating, even in sated state. This behavior can be induced in the absence of any additional factors such as palatable food or environmental stressor. However, there are a few points we must first consider; a simple increase in food consumption is different from “binge” eating. Second, binge eating is not usually driven by physical hunger (American Psychiatric Association, 2000; Waters et al., 2001). Even with the drawbacks on food restriction model, it still provides interesting aspects of eating disorders. The increase in food intake observed after fasting persists even after meeting basic metabolic needs, which reflects one characteristic of binge eating in humans (Hagan et al., 2003). Nevertheless, it is important to point out that dieting and food restriction have been shown to increase the risk of binge eating in individuals either with or without history of BN or BED (Stice et al., 2001; Stice et al., 2006).

Stress

It is well documented that stress can influence feeding behavior (Jahng, 2011; Lo et al., 2008). Animal models depicting food restriction show increases in food consumption but the effect was quite moderate. However, when fasting/refeeding paradigm is combined with food-shock stress with palatable foods, animals display binge-like increases in caloric intake (Hagan et al., 2002). This binge-like behavior is not expressed if animals are exposed to only fasting/refeeding or food-shock (Artiga et al., 2007; Chandler-Laney et al., 2007). In fact, the effect of this combination is quite specific as animals have to be exposed to at least three cycles of fasting/refeeding cycles before food-shock in order to induce binge-like

behavior (Artiga et al., 2007). Instead of physical stress such as food-shock, environmental factors can be manipulated to introduce stress such as post-natal maternal separation (MS) (Jahng, 2011). Rodents under this stress exhibit depression and anxiety-like behaviors in adulthood with imbalances in serotonin levels. However, they do not show obvious sign of hyperphagia or weight gain. Once MS is combined with repeated fasting/refeeding cycle during adolescence period, rodents start to display binge-like eating behaviors (Jahng, 2011).

It is interesting to note that stress itself does not always increase food consumption. As a matter of fact, a stress model can also be utilized to study AN as described in this review. At least in human behavior, it appears that the nature of the stressor delineates the outcome of eating behaviors. Physiological stressors such as overloaded work, interpersonal issues, or self-pride has been associated with an increase in food intake or extra-snacking between meals (Heatherton and Baumeister, 1991; O'Connor et al., 2008) whereas stressors caused by a threat of physical pain or discomfort displays the opposite behavior (Heatherton et al., 1991).

Therefore, combination of stress and fasting/refeeding paradigm captures some binge-eating behaviors but there are some caveats to it. Binge-eating behavior is more severe with palatable food than with normal chow. This leads to speculations that an increase of palatable food consumption under this model serves as an increased motivation for reward after repeated fasting. Finally, none of the models described above address one of the core criteria of either BN or BED: the sense of lack of self-control, or the emesis, following the binge-eating of BN.

Sham-feeding

There is no rodent model which reproduces postprandial vomiting. However, sham-feeding model may provide compelling evidence as a behavior model of binge-eating. Sham-feeding can be achieved with gastric fistula, by which liquid food can be drained from the opening before it enters the intestine (Smith, 1989; Smith, 1996). Under these conditions, rats show binge-like behavior consuming a large amount of food, compared to the controls with fistula closed. This model mimics purging seen in BN. However, it needs to be pointed out that drainage is by experimental manipulation and not by the animal's own intention. Nevertheless, this model can bypass the negative feedback from the intestinal system and offer insight to the physiology associated with BN.

Obesity

Obesity is an increasingly common condition in the United States and worldwide, and associated with hypertension, impaired glucose tolerance or diabetes, and dyslipidemia, which are risk factors for cardiovascular morbidity (Rader, 2007). However, is obesity an eating disorder? Eating disorders are defined as disturbances in eating habits which usually involves insufficient or excessive food intake causing energy imbalance. Hence, by this definition, obesity can be caused by abnormal eating habits but also be a consequence, not a cause, of metabolic imbalance. It is important to note that obesity is not classified as a psychological or psychiatric disorder. It is however, related to eating disorders, and it can be the consequence of BED, an identified eating disorder. Because of this relation, obesity and its animal models will be briefly described in this review. Since genetic components and the signaling pathways involved in obesity is relatively well-understood, understanding this disease state and its animal models may provide additional insight to the investigating eating disorders.

Obesity essentially results from the energy imbalance between calories ingested and total calorie expenditure. Energy balance is orchestrated by both the brain and periphery. One of the key regions of the brain involved in regulating this process is the hypothalamus (Gao and Horvath, 2007; Wynne et al., 2005). A set of systemic lesion experiments in rats identified the specific hypothalamic structures that are directly involved in energy homeostasis such as: the hypothalamic ventromedial (VMH), paraventricular (PVN) and dorsal medial (DMH) nuclei as satiety centers, and the lateral hypothalamus (LH) as the hunger center (Berthoud and Morrison, 2008; Sandoval et al., 2008). More recently, genetic deletion studies have enabled us to identify a large number of peptides and signaling cascades within the hypothalamus responsible for these feeding behaviors. Hence, food intake is now believed to be controlled by a neural circuit with specific peptides such as leptin, melanocyte-stimulating hormone- α (α -MSH), neuropeptide Y (NPY), agouti-related hormone (AgRP) and many other neuropeptides (Leibowitz and Wortley, 2004; Wynne et al., 2005).

The arcuate nucleus (ARC) is of particular importance in integrating signals for regulating appetite as it is easily accessible to circulating signals for energy balance *via* underlying median eminence (Broadwell and Brightman, 1976). Two subsets of neurons regulating food intake are found in ARC with opposing effects. The first set of cells express proopiomelanocortin (POMC) and cocaine-amphetamine regulated transcript (CART), exerting an anorexigenic effects (Boston et al., 1997; Gao and Horvath, 2007; Kristensen et al., 1998). POMC is cleaved and produces melanocyte-stimulating hormone (α -, β -, and γ -MSH). Among these, α -, and β -MSH increases energy expenditure and suppresses food intake in animals by binding to melanocortin receptor subtype 3 and 4 (MC3/4R) which are particularly abundant in the ARC, PVN, LH and DMH (Adan et al., 1994; Leibowitz and Wortley, 2004). The other group of neurons modulates orexigenic effects by NPY and AgRP (Baskin et al., 1999; Ollmann et al., 1997). NPY increases food intake and reduces energy expenditure. It is detected throughout the brain but is highly expressed in the ARC region. AgRP is a natural antagonist for MC3/4R and hence can inhibit the anorectic effects of α -MSH (Ollmann et al., 1997).

ARC has neuronal projection to LH, hypothalamic nucleus comprising two distinct neuronal populations containing neuropeptides, orexin and melanin concentrating hormone (MCH) (Qu et al., 1996). Starvation increases the expression of MCH and pre-proorexin and intracerebroventricular administration of these peptides enhances food intake (Sakurai et al., 1998). From LH, orexin-containing neurons projects to various brain regions modulating feeding (King, 2006; Qu et al., 1996; Sakurai et al., 1998). Ventromedial hypothalamus (VMH) is another important hypothalamic sites containing BDNF and receives connection from NPY/AgRP and POMC/CART neurons (Unger et al., 2007). The hypothalamus is known to be the classical center for feeding control but recent studies revealed that other areas such hindbrain or hippocampus area are also involved in eating behavior (Grill, 2006).

Genetic model

In combination with genetic tools, the contribution of animal models in obesity research is undeniable (Speakman et al., 2008). In particular, recent advances in genetic tools such as the Cre/loxP system has allowed us to manipulate gene expression both spatially and temporally, and became a powerful means to elucidate pathways that regulate body weight (Kos, 2004). There are numerous animal models which lead to obesity but describing all of them is out of scope for this review (Johnson et al., 1991; Pomp et al., 2008). Therefore, representative examples which affect eating behavior will be briefly described.

The most representative genetic models of obesity mice are ob/ob and db/db mice. The ob/ob mouse is a genetic model of leptin deficiency caused by a spontaneous mutation in the obese (ob) gene, which encodes leptin (Zhang et al., 1994), while db/db mouse has a

mutation in the leptin receptor (Chen et al., 1996). These mice have similar phenotypes such as hyperphagia, profound early-onset obesity, hyperglycemia, insulin resistance, and type-2 diabetes.

The central melanocortin system plays an essential role controlling energy homeostasis as described above. Obese agouti mice (Ay/a) bear a spontaneous mutation producing excess agouti protein which functions as an antagonist of melanocortin receptor (Miltnerberger et al., 1997; Salton et al., 2000). The role of this pathway was also demonstrated by generating MC4R knockout mice which exhibit excess weight gain, hyperphagia, hyperinsulinemia, and increased linear growth (Huszar et al., 1997). Importantly, mutations in the gene encoding MC4R are the most common form of human obesity (Farooqi et al., 2003; Vaisse et al., 2000).

The monoamine histamine is an important chemical messenger that regulates a wide variety of physiologic responses in the brain and peripheral organs (Haas et al., 2008). Four metabotropic histamine receptor types (H1R-H4R) have been cloned so far (Martinez-Mir et al., 1990; Nguyen et al., 2001). H1R-H3R are expressed in abundance in the brain and H4R mainly occurs in peripheral tissues (Haas et al., 2008). Histamine or H1R agonists injected centrally decrease the level of food intake and enhance *c-fos*-like immunoactivity in the PVN in mice, (Lecklin et al., 1998; Masaki et al., 2004; Orthen-Gambill, 1988) while blockade as well as genetic deletion of H1R elicits an increased daily food intake (Sakata et al., 1988) indicating the H1R is important for regulation of energy balance. In addition to the effect on food intake, it has been shown that brain histamine might regulate body weight and adiposity by modulating peripheral energy metabolism in rodents (Masaki and Yoshimatsu, 2006).

Some mouse strains are extremely sensitive to high-fat diet (HFD) effect on body weight. Especially, C57BL/6 mouse strain fed with HFD consistently produces severe obesity and hyperinsulinemia (Black et al., 1998). Severity of obesity is dependent of dietary fat contents. HFD-consumption is believed to be the most common cause for obesity in humans, even more so than genetic predisposition (Hill and Peters, 1998). Therefore, this model can better mimic the pathological changes in obese humans.

Conclusion

All animal models utilized in the study of eating disorders are based on clinical symptoms. The difficulties of designing appropriate animal models in eating disorders are several. First, their definitions are overlapped under current diagnostic criterion. For example, BN and BED have very similar criteria and distinction is whether binge eating behavior is associated with inappropriate compensatory mechanism such as self-induced vomiting. Unfortunately, this is not a behavior which can be easily reproduced in animal models. More importantly, the etiology of eating disorders is not clearly defined. This is partially due to is their complicated and multifactorial nature which can be influenced by social, personal, genetic, and environmental factors (Mathes et al., 2009; Oldershaw et al., 2011; Ploog and Pirke, 1987; Russell, 1979; van et al., 2009; Wolfe et al., 2009). Current animal models obviously do not encompass all of these features, but they have contributed to the current understanding of eating disorders in different ways and to different degrees. Therefore, many variations of different animal models are introduced and it is important to understand both the utility and the limitations of current models. recent advances in biomedical sciences and the ability to use genetics as a tool for understanding diseases has helped scientists develop many genetic animal models that mimic human diseases. One example, the Cre/LoxP system, enables us to manipulate the gene expression in temporal and spatial manner. Moreover, gene-environmental interaction has been also emphasized in eating disorders.

The recent discoveries and research in epigenetics has gained popularity among the scientific community. It would be a valuable tool in the characterization of eating disorders and treatments. Identification of epigenetic changes, which are often influenced by environmental changes, in the aforementioned animal models would be extremely useful in our understanding of disease progression and heritability. Advances in eating disorders etiology, onset and progression are likely to be paramount in proper animal model development for the future.

- Clinical features of eating disorders including Anorexia nervosa, bulimia nervosa, binge eating disorder are described.
- No genetic models of eating disorders are available.
- Due to the complex nature of disorders, one model cannot encompass all the clinical features.

Acknowledgments

The author apologizes to colleagues whose relevant work could not be cited because of space restrictions. This work was funded by National Alliance for Research on Schizophrenia and Depression (NARSAD) and NIH DK084336.

Reference List

- Adan RA, Cone RD, Burbach JP, Gispen WH. Differential effects of melanocortin peptides on neural melanocortin receptors. *Mol Pharmacol*. 1994; 46:1182–1190. [PubMed: 7808440]
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington DC: American Psychiatry Association; 2000.
- Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. *Ann Clin Psychiatry*. 2004; 16:75–85. [PubMed: 15328901]
- Artiga AI, Viana JB, Maldonado CR, Chandler-Laney PC, Oswald KD, Boggiano MM. Body composition and endocrine status of long-term stress-induced binge-eating rats. *Physiol Behav*. 2007; 91:424–431. [PubMed: 17498757]
- Attia E. Anorexia nervosa: current status and future directions. *Annu Rev Med*. 2010; 61:425–435. [PubMed: 19719398]
- Attia E, Schroeder L. Pharmacologic treatment of anorexia nervosa: where do we go from here? *Int J Eat Disord*. 2005; 37(Suppl):S60–S63. [PubMed: 15852322]
- Audenaert K, Van LK, Dumont F, Vervaeke M, Goethals I, Slegers G, Mertens J, van HC, Dierckx RA. Decreased 5-HT_{2A} receptor binding in patients with anorexia nervosa. *J Nucl Med*. 2003; 44:163–169. [PubMed: 12571204]
- Avraham Y, Hao S, Mendelson S, Berry EM. Tyrosine improves appetite, cognition, and exercise tolerance in activity anorexia. *Med Sci Sports Exerc*. 2001a; 33:2104–2110. [PubMed: 11740306]
- Avraham Y, Hao S, Mendelson S, Bonne O, Berry EM. Diet restriction in mice causes a decrease in hippocampal choline uptake and muscarinic receptors that is restored by administration of tyrosine: interaction between cholinergic and adrenergic receptors influencing cognitive function. *Nutr Neurosci*. 2001b; 4:153–167. [PubMed: 11842883]
- Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA, Wagner A, Thornton L, Hoge J, Ziolko SK, Becker CR, McConaha CW, Kaye WH. Exaggerated 5-HT_{1A} but normal 5-HT_{2A} receptor activity in individuals ill with anorexia nervosa. *Biol Psychiatry*. 2007; 61:1090–1099. [PubMed: 17241616]
- Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. *Diabetes*. 1999; 48:828–833. [PubMed: 10102700]

- Berthoud HR, Morrison C. The brain, appetite, and obesity. *Annu Rev Psychol.* 2008; 59:55–92. [PubMed: 18154499]
- Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry.* 2008; 165:1281–1288. [PubMed: 18558642]
- Black BL, Croom J, Eisen EJ, Petro AE, Edwards CL, Surwit RS. Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice. *Metabolism.* 1998; 47:1354–1359. [PubMed: 9826212]
- Boston BA, Blaydon KM, Varnerin J, Cone RD. Independent and additive effects of central POMC and leptin pathways on murine obesity. *Science.* 1997; 278:1641–1644. [PubMed: 9374468]
- Brandys MK, Kas MJ, van Elburg AA, Ophoff R, Slof-Op't Landt MC, Middeldorp CM, Boomsma DI, van Furth EF, Slagboom PE, Adan RA. The Val66Met polymorphism of the BDNF gene in anorexia nervosa: New data and a meta-analysis. *World J Biol Psychiatry.* 2011
- Brewerton TD, Lydiard RB, Herzog DB, Brotman AW, O'Neil PM, Ballenger JC. Comorbidity of axis I psychiatric disorders in bulimia nervosa. *J Clin Psychiatry.* 1995; 56:77–80. [PubMed: 7852257]
- Broadwell RD, Brightman MW. Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. *J Comp Neurol.* 1976; 166:257–283. [PubMed: 57126]
- Broberger C, Johansen J, Brismar H, Johansson C, Schalling M, Hokfelt T. Changes in neuropeptide Y receptors and pro-opiomelanocortin in the anorexia (anx/anx) mouse hypothalamus. *J Neurosci.* 1999; 19:7130–7139. [PubMed: 10436066]
- Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. *Proc Natl Acad Sci U S A.* 1998a; 95:15043–15048. [PubMed: 9844012]
- Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. *Proc Natl Acad Sci U S A.* 1998b; 95:15043–15048. [PubMed: 9844012]
- Brown KM, Bujac SR, Mann ET, Campbell DA, Stubbins MJ, Blundell JE. Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. *Biol Psychiatry.* 2007; 61:367–373. [PubMed: 16806108]
- Campbell LF, Bedi KS. The effects of undernutrition during early life on spatial learning. *Physiol Behav.* 1989; 45:883–890. [PubMed: 2780873]
- Casper RC. Behavioral activation and lack of concern, core symptoms of anorexia nervosa? *Int J Eat Disord.* 1998; 24:381–393. [PubMed: 9813763]
- Casper RC, Davis JM. On the course of anorexia nervosa. *Am J Psychiatry.* 1977; 134:974–978. [PubMed: 900307]
- Casper RC, Halmi KA, Goldberg SC, Eckert ED, Davis JM. Disturbances in body image estimation as related to other characteristics and outcome in anorexia nervosa. *Br J Psychiatry.* 1979; 134:60–66. [PubMed: 570073]
- Casper RC, Schoeller DA, Kushner R, Hnilicka J, Gold ST. Total daily energy expenditure and activity level in anorexia nervosa. *Am J Clin Nutr.* 1991; 53:1143–1150. [PubMed: 1850575]
- Casper RC, Sullivan EL, Tecott L. Relevance of animal models to human eating disorders and obesity. *Psychopharmacology (Berl).* 2008; 199:313–329. [PubMed: 18317734]
- Chandler-Laney PC, Castaneda E, Viana JB, Oswald KD, Maldonado CR, Boggiano MM. A history of human-like dieting alters serotonergic control of feeding and neurochemical balance in a rat model of binge-eating. *Int J Eat Disord.* 2007; 40:136–142. [PubMed: 17080436]
- Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. *Cell.* 1996; 84:491–495. [PubMed: 8608603]
- Cooper Z, Fairburn CG. Refining the definition of binge eating disorder and nonpurging bulimia nervosa. *Int J Eat Disord.* 2003; 34(Suppl):S89–S95. [PubMed: 12900989]

- Cottone P, Sabino V, Steardo L, Zorrilla EP. Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. *Neuropsychopharmacology*. 2008; 33:524–535. [PubMed: 17443124]
- Dardennes RM, Zizzari P, Tolle V, Foulon C, Kipman A, Romo L, Iancu-Gontard D, Boni C, Sinet PM, Therese BM, Estour B, Mouren MC, Guelfi JD, Rouillon F, Gorwood P, Epelbaum J. Family trios analysis of common polymorphisms in the obestatin/ghrelin, BDNF and AGRP genes in patients with Anorexia nervosa: association with subtype, body-mass index, severity and age of onset. *Psychoneuroendocrinology*. 2007; 32:106–113. [PubMed: 17197106]
- Deep AL, Nagy LM, Weltzin TE, Rao R, Kaye WH. Premorbid onset of psychopathology in long-term recovered anorexia nervosa. *Int J Eat Disord*. 1995; 17:291–297. [PubMed: 7773266]
- Eckert ED, Goldberg SC, Halmi KA, Casper RC, Davis JM. Behaviour therapy in anorexia nervosa. *Br J Psychiatry*. 1979; 134:55–59. [PubMed: 760924]
- Exner C, Hebebrand J, Remschmidt H, Wewetzer C, Ziegler A, Herpertz S, Schweiger U, Blum WF, Preibisch G, Heldmaier G, Klingenspor M. Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa. *Mol Psychiatry*. 2000; 5:476–481. [PubMed: 11032380]
- Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med*. 2003; 348:1085–1095. [PubMed: 12646665]
- Feige JN, Auwerx J. Transcriptional coregulators in the control of energy homeostasis. *Trends Cell Biol*. 2007; 17:292–301. [PubMed: 17475497]
- Fernando AB, Robbins TW. Animal models of neuropsychiatric disorders. *Annu Rev Clin Psychol*. 2011; 7:39–61. [PubMed: 21219191]
- Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC, Mathis CA, Wagner A, Hoge J, Ziolkowski S, Barbarich-Marsteller N, Weissfeld L, Kaye WH. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [¹¹C]raclopride. *Biol Psychiatry*. 2005; 58:908–912. [PubMed: 15992780]
- Galusca B, Costes N, Zito NG, Peyron R, Bossu C, Lang F, Le BD, Estour B. Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [¹⁸F]MPPF PET scan study. *Biol Psychiatry*. 2008; 64:1009–1013. [PubMed: 18639866]
- Gao Q, Horvath TL. Neurobiology of feeding and energy expenditure. *Annu Rev Neurosci*. 2007; 30:367–398. [PubMed: 17506645]
- Garfinkel PE. Perception of hunger and satiety in anorexia nervosa. *Psychol Med*. 1974; 4:309–315. [PubMed: 4427977]
- Grill HJ. Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. *Obesity (Silver Spring)*. 2006; 14(Suppl 5):216S–221S. [PubMed: 17021370]
- Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. *Physiol Rev*. 2008; 88:1183–1241. [PubMed: 18626069]
- Hagan MM, Chandler PC, Wauford PK, Rybak RJ, Oswald KD. The role of palatable food and hunger as trigger factors in an animal model of stress induced binge eating. *Int J Eat Disord*. 2003; 34:183–197. [PubMed: 12898554]
- Hagan MM, Moss DE. An animal model of bulimia nervosa: opioid sensitivity to fasting episodes. *Pharmacol Biochem Behav*. 1991; 39:421–422. [PubMed: 1946582]
- Hagan MM, Wauford PK, Chandler PC, Jarrett LA, Rybak RJ, Blackburn K. A new animal model of binge eating: key synergistic role of past caloric restriction and stress. *Physiol Behav*. 2002; 77:45–54. [PubMed: 12213501]
- Heatherton TF, Baumeister RF. Binge eating as escape from self-awareness. *Psychol Bull*. 1991; 110:86–108. [PubMed: 1891520]
- Heatherton TF, Herman CP, Polivy J. Effects of physical threat and ego threat on eating behavior. *J Pers Soc Psychol*. 1991; 60:138–143. [PubMed: 1995833]
- Hebebrand J, Casper R, Treasure J, Schweiger U. The need to revise the diagnostic criteria for anorexia nervosa. *J Neural Transm*. 2004; 111:827–840. [PubMed: 15206001]

- Hebebrand J, Exner C, Hebebrand K, Holtkamp C, Casper RC, Remschmidt H, Herpertz-Dahlmann B, Klingenspor M. Hyperactivity in patients with anorexia nervosa and in semistarved rats: evidence for a pivotal role of hypoleptinemia. *Physiol Behav.* 2003; 79:25–37. [PubMed: 12818707]
- Hill JO, Peters JC. Environmental contributions to the obesity epidemic. *Science.* 1998; 280:1371–1374. [PubMed: 9603719]
- Hillebrand JJ, Koeners MP, de Rijke CE, Kas MJ, Adan RA. Leptin treatment in activity-based anorexia. *Biol Psychiatry.* 2005; 58:165–171. [PubMed: 16038687]
- Hnasko TS, Perez FA, Scouras AD, Stoll EA, Gale SD, Luquet S, Phillips PE, Kremer EJ, Palmiter RD. Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. *Proc Natl Acad Sci U S A.* 2006; 103:8858–8863. [PubMed: 16723393]
- Holtkamp K, Herpertz-Dahlmann B, Hebebrand K, Mika C, Kratzsch J, Hebebrand J. Physical activity and restlessness correlate with leptin levels in patients with adolescent anorexia nervosa. *Biol Psychiatry.* 2006; 60:311–313. [PubMed: 16376860]
- Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell.* 1997; 88:131–141. [PubMed: 9019399]
- Idrobo F, Nandy K, Mostofsky DI, Blatt L, Nandy L. Dietary restriction: effects on radial maze learning and lipofuscin pigment deposition in the hippocampus and frontal cortex. *Arch Gerontol Geriatr.* 1987; 6:355–362. [PubMed: 3439824]
- Jahng JW. An animal model of eating disorders associated with stressful experience in early life. *Horm Behav.* 2011; 59:213–220. [PubMed: 21093444]
- Johansen JE, Broberger C, Lavebratt C, Johansson C, Kuhar MJ, Hokfelt T, Schalling M. Hypothalamic CART and serum leptin levels are reduced in the anorectic (anx/anx) mouse. *Brain Res Mol Brain Res.* 2000; 84:97–105. [PubMed: 11113536]
- Johansen JE, Fetissov S, Fischer H, Arvidsson S, Hokfelt T, Schalling M. Approaches to anorexia in rodents: focus on the anx/anx mouse. *Eur J Pharmacol.* 2003; 480:171–176. [PubMed: 14623360]
- Johnson PR, Greenwood MR, Horwitz BA, Stern JS. Animal models of obesity: genetic aspects. *Annu Rev Nutr.* 1991; 11:325–353. [PubMed: 1892704]
- Kas MJ, van DG, Scheurink AJ, Adan RA. Agouti-related protein prevents self-starvation. *Mol Psychiatry.* 2003; 8:235–240. [PubMed: 12610657]
- Kaye WH, Frank GK, Bailer UF, Henry SE. Neurobiology of anorexia nervosa: clinical implications of alterations of the function of serotonin and other neuronal systems. *Int J Eat Disord.* 2005; 37(Suppl):S15–S19. [PubMed: 15852312]
- Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. *Neuropsychopharmacology.* 1999; 21:503–506. [PubMed: 10481833]
- Keys, A.; Brozek, J.; Henschehl, A.; Mickelsen, O. *The Biology of Human Starvation.* Minneapolis, MN: The University of Minnesota Press; 1950.
- King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. *Physiol Behav.* 2006; 87:221–244. [PubMed: 16412483]
- Klein DA, Mayer LE, Schebendach JE, Walsh BT. Physical activity and cortisol in anorexia nervosa. *Psychoneuroendocrinology.* 2007; 32:539–547. [PubMed: 17462830]
- Klump KL, Strober M, Bulik CM, Thornton L, Johnson C, Devlin B, Fichter MM, Halmi KA, Kaplan AS, Woodside DB, Crow S, Mitchell J, Rotondo A, Keel PK, Berrettini WH, Plotnicov K, Pollice C, Lilienfeld LR, Kaye WH. Personality characteristics of women before and after recovery from an eating disorder. *Psychol Med.* 2004; 34:1407–1418. [PubMed: 15724872]
- Kos CH. Cre/loxP system for generating tissue-specific knockout mouse models. *Nutr Rev.* 2004; 62:243–246. [PubMed: 15291397]
- Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S. Hypothalamic CART is a new anorectic peptide regulated by leptin. *Nature.* 1998; 393:72–76. [PubMed: 9590691]
- Lambert KG, Porter JH. Pimozide mitigates excessive running in the activity-stress paradigm. *Physiol Behav.* 1992; 52:299–304. [PubMed: 1523257]

- Latner JD, Clyne C. The diagnostic validity of the criteria for binge eating disorder. *Int J Eat Disord*. 2008; 41:1–14. [PubMed: 17922537]
- Lecklin A, Etu-Seppala P, Stark H, Tuomisto L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. *Brain Res*. 1998; 793:279–288. [PubMed: 9630675]
- Leibowitz SF, Wortley KE. Hypothalamic control of energy balance: different peptides, different functions. *Peptides*. 2004; 25:473–504. [PubMed: 15134868]
- Lilenfeld LR, Wonderlich S, Riso LP, Crosby R, Mitchell J. Eating disorders and personality: a methodological and empirical review. *Clin Psychol Rev*. 2006; 26:299–320. [PubMed: 16330138]
- Lo SC, Ravaldi C, Cabras PL, Faravelli C, Ricca V. Stress, hypothalamic-pituitary-adrenal axis and eating disorders. *Neuropsychobiology*. 2008; 57:95–115. [PubMed: 18552511]
- Mancilla-Diaz JM, Escartin-Perez RE, Lopez-Alonso VE, Floran-Garduno B, Romano-Camacho JB. Role of 5-HT1A and 5-HT1B receptors in the hypophagic effect of 5-HT on the structure of feeding behavior. *Med Sci Monit*. 2005; 11:BR74–BR79. [PubMed: 15735557]
- Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. *Brain Res*. 1990; 526:322–327. [PubMed: 1979518]
- Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T, Yoshimatsu H. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. *Diabetes*. 2004; 53:2250–2260. [PubMed: 15331534]
- Masaki T, Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. *Trends Pharmacol Sci*. 2006; 27:279–284. [PubMed: 16584790]
- Mathes WF, Brownley KA, Mo X, Bulik CM. The biology of binge eating. *Appetite*. 2009; 52:545–553. [PubMed: 19501749]
- Mattar L, Huas C, Duclos J, Apfel A, Godart N. Relationship between malnutrition and depression or anxiety in Anorexia Nervosa: a critical review of the literature. *J Affect Disord*. 2011; 132:311–318. [PubMed: 20920829]
- Miltenberger RJ, Mynatt RL, Wilkinson JE, Woychik RP. The role of the agouti gene in the yellow obese syndrome. *J Nutr*. 1997; 127:1902S–1907S. [PubMed: 9278579]
- Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Mol Psychiatry*. 2005; 10:79–104. [PubMed: 15289815]
- Montague PR, Hyman SE, Cohen JD. Computational roles for dopamine in behavioural control. *Nature*. 2004; 431:760–767. [PubMed: 15483596]
- Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. *Nat Rev Drug Discov*. 2011; 10:209–219. [PubMed: 21358740]
- Nelson EE, Winslow JT. Non-human primates: model animals for developmental psychopathology. *Neuropsychopharmacology*. 2009; 34:90–105. [PubMed: 18800061]
- Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs*. 2005; 19(Suppl 1):1–93. [PubMed: 15998156]
- Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF. Discovery of a novel member of the histamine receptor family. *Mol Pharmacol*. 2001; 59:427–433. [PubMed: 11179435]
- Nilsson IA, Thams S, Lindfors C, Bergstrand A, Cullheim S, Hokfelt T, Johansen JE. Evidence of hypothalamic degeneration in the anorectic anx/anx mouse. *Glia*. 2011; 59:45–57. [PubMed: 20967882]
- O'Connor DB, Jones F, Conner M, McMillan B, Ferguson E. Effects of daily hassles and eating style on eating behavior. *Health Psychol*. 2008; 27:S20–S31. [PubMed: 18248102]
- Oldershaw A, Hambrook D, Stahl D, Tchanturia K, Treasure J, Schmidt U. The socio-emotional processing stream in Anorexia Nervosa. *Neurosci Biobehav Rev*. 2011; 35:970–988. [PubMed: 21070808]

- Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. *Science*. 1997; 278:135–138. [PubMed: 9311920]
- Orthen-Gambill N. Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. *Pharmacol Biochem Behav*. 1988; 31:81–86. [PubMed: 2908065]
- Pirke KM, Broocks A, Wilckens T, Marquard R, Schweiger U. Starvation-induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. *Neurosci Biobehav Rev*. 1993; 17:287–294. [PubMed: 7903806]
- Pirke KM, Trimborn P, Platte P, Fichter M. Average total energy expenditure in anorexia nervosa, bulimia nervosa, and healthy young women. *Biol Psychiatry*. 1991; 30:711–718. [PubMed: 1958768]
- Ploog DW, Pirke KM. Psychobiology of anorexia nervosa. *Psychol Med*. 1987; 17:843–859. [PubMed: 3324142]
- Pomonis JD, Billington CJ, Levine AS. Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. *Neuroreport*. 1996; 8:369–371. [PubMed: 9051812]
- Pomp D, Nehrenberg D, Estrada-Smith D. Complex genetics of obesity in mouse models. *Annu Rev Nutr*. 2008; 28:331–345. [PubMed: 18435591]
- Qu D, Ludwig DS, Gammeltuft S, Piper M, Pellemounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature*. 1996; 380:243–247. [PubMed: 8637571]
- Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. *Am J Med*. 2007; 120:S12–S18. [PubMed: 17320517]
- Rask-Andersen M, Olszewski PK, Levine AS, Schiøth HB. Molecular mechanisms underlying anorexia nervosa: focus on human gene association studies and systems controlling food intake. *Brain Res Rev*. 2010; 62:147–164. [PubMed: 19931559]
- Ribases M, Gratacos M, Armengol L, de CR, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez F, Estivill X. Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. *Mol Psychiatry*. 2003; 8:745–751. [PubMed: 12888803]
- Routtenberg A, Kuznesof AW. Self-starvation of rats living in activity wheels on a restricted feeding schedule. *J Comp Physiol Psychol*. 1967; 64:414–421. [PubMed: 6082873]
- Russell G. Bulimia nervosa: an ominous variant of anorexia nervosa. *Psychol Med*. 1979; 9:429–448. [PubMed: 482466]
- Saegusa Y, Takeda H, Muto S, Nakagawa K, Ohnishi S, Sadakane C, Nahata M, Hattori T, Asaka M. Decreased plasma ghrelin contributes to anorexia following novelty stress. *Am J Physiol Endocrinol Metab*. 2011; 301:E685–E696. [PubMed: 21712530]
- Sakata T, Ookuma K, Fukagawa K, Fujimoto K, Yoshimatsu H, Shiraishi T, Wada H. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. *Brain Res*. 1988; 441:403–407. [PubMed: 3359243]
- Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*. 1998; 92:1. [PubMed: 9527442]
- Salton SR, Hahn S, Mizuno TM. Of mice and MEN: what transgenic models tell us about hypothalamic control of energy balance. *Neuron*. 2000; 25:265–268. [PubMed: 10719883]
- Sandoval D, Cota D, Seeley RJ. The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. *Annu Rev Physiol*. 2008; 70:513–535. [PubMed: 17988209]
- Sarnyai Z, Alsaif M, Bahn S, Ernst A, Guest PC, Hradetzky E, Kluge W, Stelzhammer V, Wesseling H. Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders. *Int Rev Neurobiol*. 2011; 101:203–238. [PubMed: 22050853]
- Schultz W. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. *Curr Opin Neurobiol*. 2004; 14:139–147. [PubMed: 15082317]

- Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. *Nature*. 1998; 396:670–674. [PubMed: 9872314]
- Shimizu N, Oomura Y, Kai Y. Stress-induced anorexia in rats mediated by serotonergic mechanisms in the hypothalamus. *Physiol Behav*. 1989; 46:835–841. [PubMed: 2628995]
- Shroff H, Reba L, Thornton LM, Tozzi F, Klump KL, Berrettini WH, Brandt H, Crawford S, Crow S, Fichter MM, Goldman D, Halmi KA, Johnson C, Kaplan AS, Keel P, LaVia M, Mitchell J, Rotondo A, Strober M, Treasure J, Woodside DB, Kaye WH, Bulik CM. Features associated with excessive exercise in women with eating disorders. *Int J Eat Disord*. 2006; 39:454–461. [PubMed: 16637047]
- Simansky KJ. Serotonergic control of the organization of feeding and satiety. *Behav Brain Res*. 1996; 73:37–42. [PubMed: 8788474]
- Smith GP. Animal models of human eating disorders. *Ann N Y Acad Sci*. 1989; 575:63–72. [PubMed: 2699206]
- Smith GP. The direct and indirect controls of meal size. *Neurosci Biobehav Rev*. 1996; 20:41–46. [PubMed: 8622828]
- Sodersten P, Bergh C, Zandian M. Understanding eating disorders. *Horm Behav*. 2006; 50:572–578. [PubMed: 16890228]
- Speakman J, Hambly C, Mitchell S, Krol E. The contribution of animal models to the study of obesity. *Lab Anim*. 2008; 42:413–432. [PubMed: 18782824]
- Specker SM, Lac ST, Carroll ME. Food deprivation history and cocaine self-administration: an animal model of binge eating. *Pharmacol Biochem Behav*. 1994; 48:1025–1029. [PubMed: 7972280]
- Spindler SR. Caloric restriction: from soup to nuts. *Ageing Res Rev*. 2010; 9:324–353. [PubMed: 19853062]
- Stanley M, Traskman-Bendz L, Dorovini-Zis K. Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. *Life Sci*. 1985; 37:1279–1286. [PubMed: 2413327]
- Stice E, Agras WS, Telch CF, Halmi KA, Mitchell JE, Wilson T. Subtyping binge eating-disordered women along dieting and negative affect dimensions. *Int J Eat Disord*. 2001; 30:11–27. [PubMed: 11439405]
- Stice E, Martinez EE, Presnell K, Groesz LM. Relation of successful dietary restriction to change in bulimic symptoms: a prospective study of adolescent girls. *Health Psychol*. 2006; 25:274–281. [PubMed: 16719598]
- Strober M, Freeman R, Morrell W. Atypical anorexia nervosa: separation from typical cases in course and outcome in a long-term prospective study. *Int J Eat Disord*. 1999; 25:135–142. [PubMed: 10065390]
- Szczypka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. *Neuron*. 2001; 30:819–828. [PubMed: 11430814]
- Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. *Physiol Behav*. 2011; 104:590–598. [PubMed: 21664918]
- Thornton LM, Mazzeo SE, Bulik CM. The heritability of eating disorders: methods and current findings. *Curr Top Behav Neurosci*. 2011; 6:141–156. [PubMed: 21243474]
- Unger TJ, Calderon GA, Bradley LC, Sena-Estevés M, Rios M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. *J Neurosci*. 2007; 27:14265–14274. [PubMed: 18160634]
- Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. *J Clin Invest*. 2000; 106:253–262. [PubMed: 10903341]
- van Elburg AA, Kas MJ, Hillebrand JJ, Eijkemans RJ, van EH. The impact of hyperactivity and leptin on recovery from anorexia nervosa. *J Neural Transm*. 2007; 114:1233–1237. [PubMed: 17530161]
- van HD, Veling W, Sinke S, Mitchell JE, Hoek HW. The validity and utility of subtyping bulimia nervosa. *Int J Eat Disord*. 2009; 42:595–602. [PubMed: 19621467]

- Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ, Berrettini W, Hakonarson H. A genome-wide association study on common SNPs and rare CNVs in anorexia nervosa. *Mol Psychiatry*. 2011; 16:949–959. [PubMed: 21079607]
- Waters A, Hill A, Waller G. Internal and external antecedents of binge eating episodes in a group of women with bulimia nervosa. *Int J Eat Disord*. 2001; 29:17–22. [PubMed: 11135328]
- Weiselberg EC, Gonzalez M, Fisher M. Eating disorders in the twenty-first century. *Minerva Ginecol*. 2011; 63:531–545. [PubMed: 22036757]
- Wilson JF, Cantor MB. Noise-induced eating in rats facilitated by prior tail pinch experience. *Physiol Behav*. 1986; 37:523–526. [PubMed: 3749313]
- Wolfe BE, Baker CW, Smith AT, Kelly-Weeder S. Validity and utility of the current definition of binge eating. *Int J Eat Disord*. 2009; 42:674–686. [PubMed: 19610126]
- Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. *J Endocrinol*. 2005; 184:291–318. [PubMed: 15684339]
- Yokogoshi H, Nomura M. Effect of amino acid supplementation to a low-protein diet on brain neurotransmitters and memory-learning ability of rats. *Physiol Behav*. 1991; 50:1227–1232. [PubMed: 1686810]
- Zarate JM, Boksa P, Baptista T, Joover R. Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains. *Psychopharmacology (Berl)*. 2004; 171:162–172. [PubMed: 14615871]
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature*. 1994; 372:425–432. [PubMed: 7984236]